{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:54:46Z","timestamp":1792684486138,"version":"4.5.0"},"reference-count":20,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.3892\/ol.2014.2060","type":"journal-article","created":{"date-parts":[[2014,4,11]],"date-time":"2014-04-11T10:19:47Z","timestamp":1397211587000},"page":"305-308","source":"Crossref","is-referenced-by-count":6,"title":["Predictive factor and antihypertensive usage of tyrosine kinase inhibitor-induced hypertension in kidney cancer patients"],"prefix":"10.3892","volume":"8","author":[{"given":"KOUJI","family":"IZUMI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SHINGO","family":"ITAI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YOSHIKO","family":"TAKAHASHI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AERKEN","family":"MAOLAKE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MIKIO","family":"NAMIKI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2014,4,11]]},"reference":[{"key":"key20180108104645_b1-ol-08-01-0305","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(98)03544-2","article-title":"Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"key20180108104645_b2-ol-08-01-0305","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2003.02.122","article-title":"Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer","volume":"21","author":"Yang","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20180108104645_b3-ol-08-01-0305","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.2005.03.206","article-title":"Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma","volume":"23","author":"McDermott","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180108104645_b4-ol-08-01-0305","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","article-title":"Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206","volume":"28","author":"Rini","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20180108104645_b5-ol-08-01-0305","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","article-title":"Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20180108104645_b6-ol-08-01-0305","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20180108104645_b7-ol-08-01-0305","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"key20180108104645_b8-ol-08-01-0305","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20180108104645_b9-ol-08-01-0305","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1517\/17425255.2012.656845","article-title":"Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy","volume":"8","author":"Horsley","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"key20180108104645_b10-ol-08-01-0305","unstructured":"National Cancer InstituteCommon Terminology Criteria for Adverse Events v.3.0 and v.4.0 (CTCAE)http:\/\/ctep.cancer.gov\/protocolDevelopment\/adverse_effects.htmAccessed March 14, 2014"},{"key":"key20180108104645_b11-ol-08-01-0305","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1016\/j.ejca.2011.07.014","article-title":"Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma","volume":"47","author":"Tomita","year":"2011","journal-title":"Eur J Cancer"},{"key":"key20180108104645_b12-ol-08-01-0305","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1093\/annonc\/mdq221","article-title":"Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24","volume":"21","author":"Goodwin","year":"2010","journal-title":"Ann Oncol"},{"key":"key20180108104645_b13-ol-08-01-0305","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/02841860802314720","article-title":"Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis","volume":"48","author":"Zhu","year":"2009","journal-title":"Acta Oncol"},{"key":"key20180108104645_b14-ol-08-01-0305","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3747\/co.19.972","article-title":"Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents","volume":"19","author":"Larochelle","year":"2012","journal-title":"Curr Oncol"},{"key":"key20180108104645_b15-ol-08-01-0305","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"key20180108104645_b16-ol-08-01-0305","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/annonc\/mdn713","article-title":"Management of hypertension in angiogenesis inhibitor-treated patients","volume":"20","author":"Izzedine","year":"2009","journal-title":"Ann Oncol"},{"key":"key20180108104645_b17-ol-08-01-0305","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2174\/157488709788185996","article-title":"Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in urogenital cancer","volume":"4","author":"Miyajima","year":"2009","journal-title":"Rev Recent Clin Trials"},{"key":"key20180108104645_b18-ol-08-01-0305","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10552-011-9881-x","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review","volume":"23","author":"Mc Menamin","year":"2012","journal-title":"Cancer Causes Control"},{"key":"key20180108104645_b19-ol-08-01-0305","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"key20180108104645_b20-ol-08-01-0305","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","article-title":"Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Lindholm","year":"2002","journal-title":"Lancet"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2014.2060\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T08:51:28Z","timestamp":1515401488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2014.2060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,11]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,4,11]]},"published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.3892\/ol.2014.2060"],"URL":"https:\/\/doi.org\/10.3892\/ol.2014.2060","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,11]]}}}